This week in Dermatology
Nov 20, 2026
Efficacy and safety of anti-IL-4Rα stapokibart for adults with moderate-to-severe prurigo nodularis: results from a phase 3 randomized trial.
In a phase 3 placebo-controlled trial of 200 Chinese adults with prurigo nodularis, stapokibart roughly doubled meaningful itch improvement at 24 weeks, with adverse events similar to placebo.
Journal of the American Academy of Dermatology · 2026 · PubMed
This week’s highlights
Read the weekly briefing
This AudioScholar briefing is generated by artificial intelligence from PubMed abstracts for healthcare professionals and is not medical advice.
This week: a new interleukin-4 receptor antibody eases itch in prurigo nodularis, long-term remission proves attainable in anti-MDA5 dermatomyositis, and confocal microscopy spares most suspicious facial pigmented lesions from biopsy.
Welcome to This Week in Dermatology. We're covering 10 papers this week: 3 in depth, 4 in brief, 3 quick signals.
In the Journal of the American Academy of Dermatology, Zhang and colleagues report a multicentre, randomised, double-blind, placebo-controlled phase 3 trial of stapokibart, an antibody against the interleukin-4 receptor alpha, in adults with moderate-to-severe prurigo nodularis [1]. The trial enrolled 200 patients across 39 centres in China, with 100 in each arm. Patients received 300 milligrams subcutaneously every two weeks after a 600 milligram loading dose, or placebo, for 24 weeks. The primary endpoint was an improvement of at least four points on the worst itch numeric rating scale. At week 24, 64 percent of patients on stapokibart reached it, compared with 33 percent on placebo, roughly double the placebo rate. Clear or almost clear skin on the investigator global assessment for nodular prurigo was about three times as common with stapokibart, at 45 percent against 14 percent. Quality of life, skin pain, sleep disturbance and anxiety and depression scores also improved. Treatment-emergent adverse events were similar in the two arms, affecting about four in five patients on stapokibart and just under three quarters of patients on placebo. The main limitation is that every participant was Chinese, so performance in other populations is untested. The trial adds randomised phase 3 evidence for a second antibody targeting this receptor in prurigo nodularis.
JAMA Dermatology carries a retrospective cohort study led by Luo from a tertiary referral centre in China, following 523 consecutive patients with anti-MDA5 dermatomyositis for a median of almost six years [2]. More than nine in ten patients had interstitial lung disease at baseline. Deaths were concentrated early: cumulative all-cause mortality was about 28 percent at one year and rose only to about 32 percent by ten years. Low disease activity then became common, with a cumulative incidence of about 59 percent at five years and about two thirds of patients by ten years, reached after a median of roughly two years. Drug-free remission was less frequent, at about 15 percent at five years and 31 percent at ten. Respiratory failure was associated with about a third of the rate of reaching either state, while higher CD8-positive T-cell counts were associated with higher rates. Both states held up, with more than three quarters of patients still relapse-free five years later, and both went with better patient-reported global assessment and disability scores. The limitation is a retrospective design at a single centre in one population. The study adds long-horizon outcome data that have been largely missing for this high-risk subtype.
Also in the Journal of the American Academy of Dermatology, Signoret-Bravo and colleagues report a prospective single-centre study of reflectance confocal microscopy in 248 flat pigmented facial lesions clinically suspected of lentigo maligna, enrolled over about four and a half years [3]. Lesions suggestive of lentigo maligna on confocal imaging were biopsied, and the reference standard was an integrated clinical, dermoscopic, confocal and histopathological diagnosis. Confocal microscopy reached 100 percent sensitivity and about 94 percent specificity. Three quarters of the lesions, 187 in all, did not undergo biopsy after confocal assessment. Perifollicular dendritic cells were seen in every biopsy-proven lentigo maligna. Among all lentigo maligna cases, one in five had an initially negative biopsy despite suggestive confocal findings, and further histology confirmed the diagnosis in each of them. The limitations matter here. Lesions not suspicious on confocal imaging were not biopsied, so the authors acknowledge that false negatives may be underestimated, and the reference standard itself includes the confocal reading. Interpretation is operator-dependent and the setting is a single expert centre limited to facial lesions. The study adds prospective real-world support for confocal microscopy as a tool for triage and biopsy guidance in suspected facial lentigo maligna.
Now, four in brief.
In the Journal of the American Academy of Dermatology, Prajapati and colleagues report the 52-week open-label extension of the phase 3b Heads Up study [4]. Adults with moderate-to-severe atopic dermatitis who had completed 24 weeks of either dupilumab or upadacitinib all went on to upadacitinib 30 milligrams. Safety was similar whether patients continued upadacitinib or switched from dupilumab, and consistent with earlier atopic dermatitis studies. Skin clearance and itch relief were sustained with continuous upadacitinib, and by the end of the extension, patients who switched from dupilumab had responses generally comparable to those on continuous treatment. The open-label, uncontrolled design means this is supportive evidence on switching rather than a randomised comparison.
Also on long-term biologic use, Acta Dermato-Venereologica carries a retrospective multicentre study from Expósito-Serrano and colleagues of 144 patients with isolated chronic inducible urticaria treated with off-label omalizumab [5]. At six months, close to three quarters of patients had complete or good control. Complete control was more common in solar urticaria than in symptomatic dermographism, at about 69 against 32 percent. About a quarter of patients needed updosing, and higher body mass index was linked to less complete control and more dose escalation. Drug survival was about 72 percent at five years, and half of all discontinuations were for remission. Baseline clinical and serum biomarkers did not predict response or drug survival. This is real-world retrospective evidence, not controlled efficacy data.
From the British Journal of Dermatology, Stadler and colleagues profiled formalin-fixed biopsies from 96 patients with erythroderma of five causes, plus 20 healthy controls, from four centres, using mass spectrometry proteomics and RNA sequencing [6]. Each disease showed a distinct molecular signature, including Charcot-Leyden crystal protein in atopic dermatitis, the T-cell regulator RASAL3 in cutaneous T-cell lymphoma, and interleukin-17C upregulation in only a subset of patients with pityriasis rubra pilaris, which the authors read as possible treatment-relevant endotypes. A machine-learning classifier reached about 74 percent accuracy in a held-out test set, against about 60 percent for blinded clinico-histopathological assessment. With around twenty patients per disease, the authors present this as proof of concept.
Pityriasis rubra pilaris also appears in Acta Dermato-Venereologica, where Tartaglia and colleagues pooled 14 observational studies covering 464 biologic treatment courses in a systematic review and meta-analysis [7]. About three quarters of courses produced some response, while complete or near-complete response occurred in about a third. Interleukin-23 pathway inhibitors had the highest complete response rate, at about 55 percent, against roughly a quarter for tumour necrosis factor inhibitors and a fifth for interleukin-17 inhibitors, but the difference between classes was not statistically significant. Adverse events were reported in 12 of 183 courses with safety data. Observational designs and small denominators leave class comparisons uncertain, and together with the endotype finding above, both papers point to heterogeneous response in this disease.
Three quick signals.
A narrative review in the Journal of the American Academy of Dermatology from Shen and colleagues covers viral vector therapies: oncolytic herpes simplex virus therapy in advanced melanoma, including after checkpoint inhibitor progression, and topical beremagene geperpavec for durable wound closure in dystrophic epidermolysis bullosa [8]. The authors note that many other applications rest only on early-phase or preclinical data.
Also in that journal, the second part of a review on sarcoidosis for dermatologists, led by Balan, covers treatment ranging from local therapy to systemic immunosuppression, individualised to extent and severity, with monitoring guided by symptoms, organ involvement and the drugs in use [9]. It is an expert narrative review rather than new data.
Finally, a review in the Journal of Investigative Dermatology from Alavi and colleagues on pyoderma gangrenosum describes diagnostic delay driven by subjective criteria and the lack of a specific biomarker, sometimes ending in amputation, alongside limited treatment options and the role of wound care and pain relief [10]. It is a narrative review without new data.
Stepping back across this week's papers, the firmest evidence came from a single randomised trial, while much of the rest rested on retrospective cohorts, an open-label extension, pooled observational series and narrative reviews. Several rare-disease questions, from classifying erythroderma to choosing a biologic class in pityriasis rubra pilaris, are being approached with small groups per condition. One diagnostic study built its reference standard partly from the tool under test. Randomised comparisons in these rare conditions remain scarce.
If you only have time for one paper this week, make it the stapokibart trial in prurigo nodularis [1]. It is the week's only randomised placebo-controlled trial, and it extends phase 3 evidence for interleukin-4 receptor alpha blockade in prurigo nodularis to a second agent, while leaving open how it performs outside Chinese patients.
That's your roundup for This Week in Dermatology. The full transcript and references are available on the episode page. See you next week.
If this weekly briefing is useful, follow the show in your podcast app so new episodes arrive automatically. And think of one colleague, in any specialty, who never has time to keep up with the literature. Tell them about AudioScholar: a ten-minute weekly for every specialty, to listen to in any podcast app, or to read at audioscholar dot C C.
This is an automated summary generated by artificial intelligence, which can make mistakes. Use it to choose which papers to read in full.
Get Dermatology every week
By email, Spotify, Apple or any podcast app.
Spot something worth flagging?